These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 53574)

  • 1. Letter: Toxicity of intravenous Corynebacterium parvum.
    Ossorio RC; Fahey JL; Wilson W; Plotkin D; Brossman S; Skinner D
    Lancet; 1975 Nov; 2(7944):1090-1. PubMed ID: 53574
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: Side-effects of intravenous Corynebacterium parvum.
    Hamilton DN
    Lancet; 1975 Dec; 2(7947):1263. PubMed ID: 53755
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prevention of accidents from serotherapy].
    Cruchaud A
    Schweiz Med Wochenschr; 1966 Sep; 96(35):1124-6. PubMed ID: 4384934
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter: Corynebacterium parvum and anaesthetics.
    Mosedale B; Smith MA
    Lancet; 1975 Jan; 1(7899):168. PubMed ID: 46085
    [No Abstract]   [Full Text] [Related]  

  • 5. Toxicity manifestations following intravenous Corynebacterium parvum administration to patients with ovarian and cervical carcinoma.
    Gall SA; DiSaia PJ; Schmidt H; Mittelstaedt L; Newman P; Creasman W
    Am J Obstet Gynecol; 1978 Nov; 132(5):555-60. PubMed ID: 717456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection by Corynebacterium parvum against tumour cells injected intravenously.
    Milas L; Mujagić H
    Rev Eur Etud Clin Biol; 1972 May; 17(5):498-500. PubMed ID: 4648182
    [No Abstract]   [Full Text] [Related]  

  • 7. [Preliminary considerations on the intravenous use of Corynebacterium parvum in the treatment of solid neoplasms].
    Scheinberg MA; Sartori JP; de Pinho JG
    AMB Rev Assoc Med Bras; 1979 Apr; 25(4):139-40. PubMed ID: 315598
    [No Abstract]   [Full Text] [Related]  

  • 8. Design of phase-I trials of immunopotentiators for cancer therapy: levamisole and Corynebacterium parvum.
    Hirshaut Y; Pinsky CM; Wanebo HJ; Oettgen HF
    Ann N Y Acad Sci; 1976; 277(00):252-9. PubMed ID: 793480
    [No Abstract]   [Full Text] [Related]  

  • 9. Corynebacterium parvum toxicity.
    Sexauer CL; Nitschke R; Humphrey GB
    Lancet; 1976 Jul; 2(7978):199. PubMed ID: 73819
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of C. parvum on the effectiveness of passive serotherapy in the control of the EL4 lymphoma in C57BL/6 mice.
    O'Neill GJ; Stebbing N
    Br J Cancer; 1980 Feb; 41(2):243-9. PubMed ID: 7370164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung cancer patients treated with Corynebacterium parvum. Phase I toxicity study.
    Yadeau R; Bates HA; Fortuny I
    Minn Med; 1979 Sep; 62(9):673-5. PubMed ID: 503003
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunological response in patients receiving Corynebacterium parvum therapy.
    Osborn DE; Castro JE
    Clin Oncol; 1977 Jun; 3(2):155-64. PubMed ID: 872468
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of Corynebacterium parvum on the immune response in guinea pigs. II. Passive transfer of enhanced anamnestic response and delayed hypersensitivity observed after treatment with Corynebacterium parvum].
    Halpern B; Gauthier-Rahman S; Besluau D
    C R Seances Soc Biol Fil; 1977; 171(6):1209-16. PubMed ID: 148949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of antitumor action of Corynebacterium parvum: the generation of cell-mediated tumor specific immunity.
    Tuttle RL; North RJ
    J Reticuloendothel Soc; 1976 Sep; 20(3):197-208. PubMed ID: 978659
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunoglobulin therapy.
    Lancet; 1991 Jul; 338(8760):157-8. PubMed ID: 1677073
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of Corynebacterium parvum on the course of a Listeria monocytogenes infection in normal and congenitally athymic (nude) mice.
    Ruittenberg EJ; van Noorle Jansen LM
    Zentralbl Bakteriol Orig A; 1975; 231(1-3):197-205. PubMed ID: 808049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corynebacterium parvum as a therapeutic antitumor agent in mice. I. Systemic effects from intravenous injection.
    Scott MT
    J Natl Cancer Inst; 1974 Sep; 53(3):855-60. PubMed ID: 4213015
    [No Abstract]   [Full Text] [Related]  

  • 18. A comparison of the toxicity of two formulations of Corynebacterium parvum in a double-blind crossover trial in patients with bronchogenic carcinoma.
    Mitcheson HD; Priestman TJ
    Clin Oncol; 1981 Sep; 7(3):179-82. PubMed ID: 7044635
    [No Abstract]   [Full Text] [Related]  

  • 19. The complications of intravenous Corynebacterium parvum infusion.
    Gill PG; Morris PJ; Kettlewell M
    Clin Exp Immunol; 1977 Nov; 30(2):229-32. PubMed ID: 606444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of Corynebacterium parvum presensitization to modify the antitumor effects of systemic and local therapeutic injections of C. parvum in mice.
    Scott MT
    J Natl Cancer Inst; 1976 Mar; 56(3):675-7. PubMed ID: 815560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.